Browse report sample at: https://www.psmarketresearch.com/market-analysis/retinitis-pigmentosa-therapeutics-pipeline-analysis/report-sample
Many companies are increasingly emphasizing on the development of gene therapy candidates, due to their positive clinical results in the treatment of retinitis pigmentosa. Based on molecule type, around 50.0% of the drug candidates in the retinitis pigmentosa pipeline are expected to be developed based on gene therapy.
Technological advancements are spurring the pipeline growth, for instance, AAV vector manufacturing platform was used in the development of AGTC-501 by the Applied Genetic Technologies Corp for the treatment of retinitis pigmentosa.
Browse report at: https://www.psmarketresearch.com/market-analysis/retinitis-pigmentosa-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of retinitis pigmentosa include jCyte, Inc., Dompe Farmaceutici SpA, ProRetina Therapeutics, S.L., and Recursion Pharmaceuticals Inc.
About
P&S Intelligence
P&S
Intelligence, a brand of P&S Market Research, is a provider of market
research and consulting services catering to the market information needs of
burgeoning industries across the world. Providing the plinth of market
intelligence, P&S as an enterprising research and consulting company,
believes in providing thorough landscape analyses on the ever-changing market
scenario, to empower companies to make informed decisions and base their
business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886
(USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
0 Comments